January 9, 2024 – The project officially began with the approval of the study by the Ethics Committee of the University of Cagliari. This marked a fundamental milestone, providing the scientific and regulatory validation required to launch the research.

January 2024 – Shortly after approval, patient enrollment started. This crucial phase laid the foundation of the study, allowing the research team to begin collecting the first clinical data needed for future analyses.

March 3, 2025 – The study protocol was formally published in PubMed, making the project methodology available to the international scientific community. Read the publication.

April 12, 2025 – The results of the systematic review were released, also indexed in PubMed. This work provided a comprehensive overview of the existing evidence, supporting the rationale and relevance of the MINERVA study. Read the publication.

January 2025 – The patient enrollment phase was completed, successfully reaching the target population for the study. This step represents a turning point, allowing the project to move forward into the monitoring and follow-up phase.

January 2026 – The follow-up of patients will be completed, closing the observation period one year after enrollment. This will provide the final dataset for the analysis of outcomes.

February 2026 – The project will reach its official conclusion, with the final results expected to be shared with the scientific community through publications and dedicated dissemination activities.